Robert Liddell

Assistant Professor

Johns Hopkins University School of Medicine
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Robert Liddell is an Assistant Professor at Johns Hopkins School of Medicine in the United States. His research focuses on interventional oncology, particularly advancements in tumor ablation techniques and treatment options for metastatic colorectal cancer. His recent articles include studies on transarterial radioembolization, cryoablation, and evidence-based guidelines for image-guided procedures.

Articles (16)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Approximately 25% of patients with colorectal cancer present with metastatic disease to the liver at diagnosis, and about 50% develop liver metastases at some point during the course of the disease. Surgical resection of hepatic metastases remains the gold standard treatment for liver metastases. However, many patients with colorectal liver metastases (CRLMs) are not eligible for up-front resection. Despite advances in systemic chemotherapy, long-term survival continues to be strongly influenced by liver-directed treatments. A multidisciplinary approach is recommended for all patients, with a combination of systemic therapy and one or more liver-directed local treatments determined based on the goals of therapy. For unresectable CRLM (uCRLM), hepatic artery infusion pump therapy, stereotactic body radiation therapy (SBRT), image-guided ablation, and transarterial chemo- or radioembolization are local-regional options to consider. More recently, emerging evidence supports the use of liver transplantation in selected patients with uCRLM. This chapter reviews the spectrum of liver-directed therapies, their outcomes, and ongoing developments regarding local regional therapies for uCRLM.

Year:

2026

Objectives: The objectives of the study are to compare the effect on image quality of a motion artifact correction algorithm (CAVAREC) alone versus in combination with an automated bone removal algorithm (ZIBOS) for motion-degraded intraprocedural liver cone-beam computed tomography (CBCT) images. Material and Methods: In this retrospective, two-center, Institutional Review Board (IRB)-approved study, 48 CBCTs from 41 patients were included. Inclusion criteria were (a) age ≥18; (b) liver CBCT with contrast injected at the main, right, or left hepatic artery; and (c) CBCT motion-degraded. Exclusion criteria were (a) no visible tumor and (b) CBCT not capturing the entire liver. The mean (standard deviation [SD]) age was 64 (7) years, 81% male. 65% had hepatocellular carcinoma and 35% metastatic cancer. 69% CBCTs were from transarterial radioembolization (TARE) mapping, 25% transarterial chemoembolization, and 6% TARE treatment. Mean (SD) maximum tumor diameter was 4.6 (2.7) cm. CBCT images were processed with CAVAREC (prototype, Siemens Healthineers AG, Forchheim, Germany) and CAVAREC + ZIBOS (work in progress, Comprehenso, Hannover, Germany). Using CoroEval, sharpness for two segmental arteries per case was obtained quantitatively. Three blinded interventional radiologists independently evaluated overall image quality on a 0–100 scale and large vessels, small vessels, vessel sharpness, tumor feeders, tumor blush, and streak artifacts on a −50 to +50 scale relative to uncorrected images. Results were analyzed with paired t- tests and Wilcoxon signed-rank tests, adjusting P -values with the Benjamini–Hochberg procedure. Results: On quantitative assessment, mean (SD) sharpness for uncorrected, CAVAREC, and CAVAREC + ZIBOS (C+Z) images was 0.281 (0.04), 0.287 (0.04), and 0.284 (0.04), respectively, P = 0.02 for uncorrected versus CAVAREC and P > 0.05 for other comparisons. On qualitative assessment, mean (SD) overall quality for uncorrected, CAVAREC, and C+Z images was 45 (14), 53 (16), and 53 (17), respectively, P 0.05. CAVAREC versus C+Z was not significant for any parameter. Conclusion: Motion artifact correction of liver CBCT images using CAVAREC improves image quality significantly. According to observer studies, integrating the automated bone segmentation algorithm ZIBOS with CAVAREC does not degrade image quality.

Year:

2025

Year:

2025

Surgical resection for localized hepatocellular carcinoma (HCC) is typically reserved for a minority of patients with favorable tumor features and anatomy. Neoadjuvant immunotherapy can expand the number of patients who are candidates for surgical resection and potentially reduce the chance for recurrence, but its role in HCC not defined. We retrospectively examined the outcomes of patients who underwent surgical resection for HCC at the Johns Hopkins Hospital and compared the clinical outcomes of patients who received neoadjuvant immunotherapy with those who underwent upfront resection. The clinical cohort included a total of 92 patients, 36 of whom received neoadjuvant immune checkpoint inhibitor (ICI)-based treatment. A majority of patients (61.1%) who received neoadjuvant ICI–based therapy were outside of standard resectability criteria and were more likely to have features known to confer risk of disease recurrence, including α-fetoprotein ≥ 400 ng/mL ( P = 0.02), tumor diameter ≥ 5 cm ( P = 0.001), portal vein invasion ( P P P = 0.47) and recurrence-free survival (RFS) as those who underwent upfront surgical resection (median RFS 44.8 months compared with 49.3 months, respectively, log-rank P = 0.66). There was a nonsignificant trend toward superior RFS in the subset of patients with a pathologic response (tumor necrosis ≥ 70%) with neoadjuvant immunotherapy. Neoadjuvant ICI-based therapy may allow high-risk patients, including those who are outside traditional resectability criteria, to achieve comparable clinical outcomes with those who undergo upfront resection. Significance: Surgical resection for localized HCC is typically only reserved for those with solitary tumors without vascular invasion. In this retrospective analysis, we show that neoadjuvant immunotherapy may allow high-risk patients, including those who are outside of standard resection criteria, to undergo successful margin-negative resection and achieve comparable long-term clinical outcomes compared with upfront resection. These findings highlight need for prospective studies on neoadjuvant immunotherapy in HCC.

Year:

2024

Surgical resection for localized hepatocellular carcinoma (HCC) is typically reserved for a minority of patients with favorable tumor features and anatomy. Neoadjuvant immunotherapy can expand the number of patients who are candidates for surgical resection and potentially reduce the chance for recurrence, but its role in HCC not defined. We retrospectively examined the outcomes of patients who underwent surgical resection for HCC at the Johns Hopkins Hospital and compared the clinical outcomes of patients who received neoadjuvant immunotherapy with those who underwent upfront resection. The clinical cohort included a total of 92 patients, 36 of whom received neoadjuvant immune checkpoint inhibitor (ICI)-based treatment. A majority of patients (61.1%) who received neoadjuvant ICI–based therapy were outside of standard resectability criteria and were more likely to have features known to confer risk of disease recurrence, including α-fetoprotein ≥ 400 ng/mL ( P = 0.02), tumor diameter ≥ 5 cm ( P = 0.001), portal vein invasion ( P P P = 0.47) and recurrence-free survival (RFS) as those who underwent upfront surgical resection (median RFS 44.8 months compared with 49.3 months, respectively, log-rank P = 0.66). There was a nonsignificant trend toward superior RFS in the subset of patients with a pathologic response (tumor necrosis ≥ 70%) with neoadjuvant immunotherapy. Neoadjuvant ICI-based therapy may allow high-risk patients, including those who are outside traditional resectability criteria, to achieve comparable clinical outcomes with those who undergo upfront resection. Significance: Surgical resection for localized HCC is typically only reserved for those with solitary tumors without vascular invasion. In this retrospective analysis, we show that neoadjuvant immunotherapy may allow high-risk patients, including those who are outside of standard resection criteria, to undergo successful margin-negative resection and achieve comparable long-term clinical outcomes compared with upfront resection. These findings highlight need for prospective studies on neoadjuvant immunotherapy in HCC.

Year:

2024

Surgical resection for localized hepatocellular carcinoma (HCC) is typically reserved for a minority of patients with favorable tumor features and anatomy. Neoadjuvant immunotherapy can expand the number of patients who are candidates for surgical resection and potentially reduce the chance for recurrence, but its role in HCC not defined. We retrospectively examined the outcomes of patients who underwent surgical resection for HCC at the Johns Hopkins Hospital and compared the clinical outcomes of patients who received neoadjuvant immunotherapy with those who underwent upfront resection. The clinical cohort included a total of 92 patients, 36 of whom received neoadjuvant immune checkpoint inhibitor (ICI)-based treatment. A majority of patients (61.1%) who received neoadjuvant ICI–based therapy were outside of standard resectability criteria and were more likely to have features known to confer risk of disease recurrence, including α-fetoprotein ≥ 400 ng/mL (P = 0.02), tumor diameter ≥ 5 cm (P = 0.001), portal vein invasion (P < 0.001), and multifocality (P < 0.001). Patients who received neoadjuvant immunotherapy had similar rates of margin-negative resection (P = 0.47) and recurrence-free survival (RFS) as those who underwent upfront surgical resection (median RFS 44.8 months compared with 49.3 months, respectively, log-rank P = 0.66). There was a nonsignificant trend toward superior RFS in the subset of patients with a pathologic response (tumor necrosis ≥ 70%) with neoadjuvant immunotherapy. Neoadjuvant ICI-based therapy may allow high-risk patients, including those who are outside traditional resectability criteria, to achieve comparable clinical outcomes with those who undergo upfront resection. Significance: Surgical resection for localized HCC is typically only reserved for those with solitary tumors without vascular invasion. In this retrospective analysis, we show that neoadjuvant immunotherapy may allow high-risk patients, including those who are outside of standard resection criteria, to undergo successful margin-negative resection and achieve comparable long-term clinical outcomes compared with upfront resection. These findings highlight need for prospective studies on neoadjuvant immunotherapy in HCC.

Year:

2024

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Collaborators (8)

Mark Yarchoan

Johns Hopkins University

UNITED STATES
View details

Alexandra Strauss

Johns Hopkins University

UNITED STATES
View details

Marina Baretti

Assistant Professor

Johns Hopkins University

UNITED STATES
View details

Won Jin Ho

Johns Hopkins University School of Medicine

UNITED STATES
View details

Patrick Bourgouin

Clinical Associate Professor

Université de Montréal

CANADA
View details

Jin He

Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

William Burns

Assistant Professor

Johns Hopkins University School of Medicine

UNITED STATES
View details

Richard A. Burkhart

Johns Hopkins University School of Medicine

UNITED STATES
View details